Atherosclerosis
-
Meta Analysis
Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.
Chronic kidney disease is a strong independent predictor of cardiovascular disease. No published meta-analyses on the use of aspirin for the primary prevention of cardiovascular disease in chronic kidney disease exist. We therefore performed a systematic review and meta-analysis of this subject. ⋯ There is no clear benefit of aspirin for the primary prevention of cardiovascular events in CKD and no statistically significant reduction in mortality. Aspirin is likely to increase the risk of major bleeding events. Currently, insufficient randomised control trial data exists to recommend universal use or avoidance of aspirin for primary prevention of cardiovascular events in CKD.